$-0.11 EPS Expected for Applied DNA Sciences Inc (APDN)

November 19, 2017 – By Winifred Garcia

Investors sentiment decreased to 0.73 in 2017 Q2. Its down 0.65, from 1.38 in 2017Q1. It fall, as 4 investors sold Applied DNA Sciences Inc shares while 7 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.49 million shares or 25.31% less from 3.33 million shares in 2017Q1 were reported.
Morgan Stanley holds 0% of its portfolio in Applied DNA Sciences Inc (NASDAQ:APDN) for 112,834 shares. Sabby Lc, a New Jersey-based fund reported 987,593 shares. Geneva Advsrs Ltd Co invested in 0% or 35,196 shares. Chase Investment Counsel accumulated 77,563 shares. D Scott Neal holds 0% of its portfolio in Applied DNA Sciences Inc (NASDAQ:APDN) for 384 shares. California Employees Retirement Sys accumulated 36,200 shares. Natl Bank Of Mellon holds 17,200 shares. Benchmark Capital Advisors has invested 0.07% in Applied DNA Sciences Inc (NASDAQ:APDN). Commonwealth Equity Serv Inc accumulated 19,694 shares or 0% of the stock. Dumont Blake Ltd Company holds 18,412 shares. Wells Fargo Mn stated it has 0% of its portfolio in Applied DNA Sciences Inc (NASDAQ:APDN). New York-based Goldman Sachs Grp Inc Inc Inc has invested 0% in Applied DNA Sciences Inc (NASDAQ:APDN). The Kansas-based Creative Planning has invested 0% in Applied DNA Sciences Inc (NASDAQ:APDN). Fincl Bank Of Montreal Can invested in 0% or 12,200 shares. Taurus Asset Mgmt Ltd Limited Liability Company stated it has 0% in Applied DNA Sciences Inc (NASDAQ:APDN).

Analysts expect Applied DNA Sciences Inc (NASDAQ:APDN) to report $-0.11 EPS on December, 5.They anticipate $0.01 EPS change or 10.00 % from last quarter’s $-0.1 EPS. After having $-0.10 EPS previously, Applied DNA Sciences Inc’s analysts see 10.00 % EPS growth. The stock increased 5.88% or $0.13 on November 17, reaching $2.34. About 39,570 shares traded. Applied DNA Sciences Inc (NASDAQ:APDN) has declined 49.09% since November 19, 2016 and is downtrending. It has underperformed by 65.79% the S&P500.

Applied DNA Sciences, Inc. is engaged in creating security solutions addressing the challenges of modern commerce. The company has market cap of $64.06 million. The Firm is also engaged in the large-scale production of specific deoxyribonucleic acid sequences using the polymerase chain reaction (PCR). It currently has negative earnings. The Company’s principal technology platform includes SigNature DNA, SigNature T DNA, fiberTyping, DNAnet, digitalDNA, SigNify and Beacon.

Another recent and important Applied DNA Sciences Inc (NASDAQ:APDN) news was published by Marketwired.com which published an article titled: “Applied DNA Sciences Signs 5-Year Supply Agreement for Bulk DNA Manufacturing” on April 20, 2017.